Skip to main content

Cerdelga FDA Approval History

FDA Approved: Yes (First approved August 19, 2014)
Brand name: Cerdelga
Generic name: eliglustat
Dosage form: Capsules
Company: Genzyme Corporation
Treatment for: Gaucher Disease

Cerdelga (eliglustat) is a glucosylceramide synthase inhibitor indicated for the long- term treatment of adult patients with Gaucher disease type 1.

Development timeline for Cerdelga

DateArticle
Aug 19, 2014Approval FDA Approves Cerdelga (eliglustat) for Type 1 Gaucher Disease
Dec 11, 2013FDA Grants Priority Review for Genzyme’s Cerdelga (eliglustat), an Investigational Oral Therapy for Gaucher Disease

See also

Cerdelga (eliglustat) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer